아토목세틴

아토목세틴 C화학적 특성, 용도, 생산

용도

p-Tolyloxy Atomoxetine Hydrochloride is an impurity of Atomoxetine Hydrochloride(A791400) which is a norepinephrine reuptake inhibitor.

Pharmacokinetics

Atomoxetine is well absorbed from the GItract and cleared primarily by metabolism, with the majority of the dose being excreted into the urine. Atomoxetine is metabolized primarily by CYP2D6 to its major active metabolite, 4-hydroxyatomoxetine, which is eliminated as its glucuronide. Peak plasma concentrations of atomoxetine occur 1 to 2 hours after oral administration. Significant differences are seen in the elimination half-life between normal metabolizers, extensive metabolizers, and poor metabolizers. Atomoxetine exhibited an elimination half-life of 3 to 6 hours for normal and extensive metabolizers and 17 to 21 hours for poor metabolizers. CYP2C19 is the other enzyme primarily responsible for the formation of its minor metabolite N-desmethylatomoxetine.

Clinical Use

Atomoxetine is used as a safe and well-tolerated “nonstimulant” treatment of ADHD in both adults and children and of depression. Among children and adolescents aged 8 to 18 years, atomoxetine was superior to placebo in reducing symptoms of ADHD and in improving social and family functioning symptoms. Oral atomoxetine is promoted as an alternative to conventional ADHD therapy with methylphenidate, dextroamphetamine, and pemoline. It also can be a replacement for bupropion or for TCAs. Onset of action is approximately 7 days.

부작용

At therapeutic doses, no serious drug-related adverse effects have been encountered. Adverse effects have included modest increases in diastolic blood pressure and heart rate, anorexia, weight loss, somnolence, dizziness, GI effects (nausea), dry mouth, and skin rash.

효소 저해제

This ADHD drug (FWfree-base = 255.36 g/mol; FWhydrochloride = 291.81 g/mol; CAS 83015-26-3), also known as LY139603, Strattera?, and systematically as (3R) -N-methyl-3- (2-methylphenoxy) -3-phenylpropan-1-amine; (R) -N- methyl-3-phenyl-3- (o-tolyloxy) -propan-1-amine, potently inhibits the presynaptic norepinephrine transporter, Ki = 4.5 nM and is used to treat depression and attention-deficit/hyperactivity disorder. In 2002, Strattera became the first FDA-approved nonstimulant for the treatment of ADHD. The mechanism of action is related to its selective inhibition of presynaptic norepinephrine reuptake in the prefrontal cortex. Atomoxetine demonstrates high affinity and selectivity for norepinephrine transporters, but little or no affinity for neurotransmitter receptors. Atomoxetine demonstrates preferential binding to areas of known high distribution of noradrenergic neurons, such as the fronto-cortical subsystem. Atomoxetine undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP2D6) in a small percentage of the population. (Note: Atomoxetine was originally named tomoxetine, but was changed to avoid any potential confusion with tamoxifen.) Key Pharmacokinetic Parameters: See Appendix II in Goodman & Gilman’s THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 12th Edition (Brunton, Chabner & Knollmann, eds.) McGraw-Hill Medical, New York.

아토목세틴 준비 용품 및 원자재

원자재

준비 용품

아토목세틴 공급 업체

공급자	전화	이메일	국가	제품 수	이점
China National Standard Pharmaceutical Corporation Limited	+8615391658522	overseasales@yongstandards.com	China	11922	58
QUALITY CONTROL SOLUTIONS LTD.	0755-66853366; 13670046396	ORDERS@QCSRM.COM	China	24326	58
Beijing Comparison Pharmaceutical Technology Co., Ltd	010-010-52878169 15801002657	sales@bjcomparison.com	China	4949	58
ChemStrong Scientific Co.,Ltd	0755-0755-66853366 13670046396	sales@chem-strong.com	China	18043	56
Shandong Boluoda Biological Technology Co., Ltd.	0531-58190570 15863796298	2310993908@qq.com	China	1298	58
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	8011	62
Hubei Yangxin Medical Technology Co., Ltd.	15374522761	3003392093@qq.com	China	8376	55
Guangzhou Dreampharm Biotechnology Co., Ltd.	020-36607679 17825480238	3008233717@qq.com	China	9919	12
Jinan blalong chemical co. LTD	2710913286@.com	1513643261@qq.com	China	14246	58
Shenzhen ruikai de biotechnology co., ltd.	0755-61348847 17820674378	2682116078@qq.com	China	7843	58

아토목세틴 관련 검색: